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Abstract 
Background: The plasma amino acid profile can be a useful indicator in clinical 
settings because it changes in response to various metabolic alternations. However, the 
association between the plasma amino acid profile and body fat accumulation has not 
been evaluated in humans. 
Objective: This study aimed to relate plasma amino acids to visceral fat accumulation 
in humans because excess visceral fat raises the odds ratio of developing metabolic 	
syndrome. 

Design: A total of 1,449 subjects (985 males and 464 females) who had undergone a 
comprehensive health screening were enrolled in this study. The visceral fat area (VFA) 
was determined in each subject using CT imaging. Subjects were then divided into two 
groups according to VFA: high-VFA (100 cm2, n=867) and low-VFA (<100 cm2, 
n=582). The plasma amino acid profile was analyzed together with other metabolic 
valuables and then compared between the two groups using uni- and multivariate 
analyses.  
Results: As the degree of visceral fat accumulation increased, plasma concentrations of 
several amino acids changed significantly. Glu, Val, Leu, Ile, Tyr, Ala, Phe, Pro, Lys, 	
Orn, Trp, Met, His and alpha-aminobutyric acid (ABA) levels were significantly higher 

in the high-VFA group compared to the low-VFA group, whereas the levels of Gly, Ser, 
Gln and Asn were significantly lower. To evaluate the potential of using amino acids as 
an indicator of VFA, a discriminant analysis was conducted with the multivariate 
logistic regression analysis “AminoIndex”, and the ROC curve was calculated. The 
resulting “AminoIndex” exhibited an area under the ROC curve of 0.81 (95% 
confidence interval; 0.78 to 0.83), with higher sensitivity and specificity by 80% and 
 
65%, respectively. 
Conclusions: The plasma amino acid profile changes depending on visceral fat content 
and can be used as a marker for diagnosing elevated visceral obesity in humans. 
 
 
Introduction 
Recent progress in metabolomics has enables the high throughput measurement of 
diverse amino acids 1-3 and has shown the new possibility of using amino acid analysis 
of biological samples as a biomarker discovery tool by generating diagnostic indices 
through systematic multivariate regression models4. Published studies have shown that 
amino acids in biological fluids change in response to metabolic alternations during the 
courses of various diseases, such as renal failure5, cancer6, atherosclerosis7, and insulin 	
resistance8. The balance between branched amino acids (Leu, Val and Ile; BCAA) and 

aromatic amino acids (Phe and Tyr; AAA) is known as Fischer’s ratio and is one of a 
few classical indicators used to monitor hepatic encephalopathy9. Recently, a novel 
multivariate logistic regression model of plasma free amino acids (“AminoIndex”) was 
reported for the discrimination of various disease states in rat models of type-1 and 
type-2 diabetes 10and the progression of liver fibrosis in chronic hepatitis C in humans11. 
Furthermore, the usefulness of amino acid profiles in various tissues in combination 
with other “-omics” datasets has been reported for investigating metabolic and 
regulatory networks in animals12, 13. 
Recent studies have suggested that there may be an association between plasma 	
amino acid levels and obesity in both animals and humans. For instance, elevated 

plasma BCAAs and glutamate were observed in obese rodents 14, 15 and humans16. The 
plasma ratio of Trp/large neutral amino acids was also lower in obese subjects16, 17. 
Furthermore, a reduction in the levels of Gly, Trp, Thr, His, taurine, citrulline and 
cystine has been reported in obese subjects16. These studies strongly indicate that the 
volume of adipose tissue or its dysfunctions could affect amino acid metabolism and the 
levels of amino acids in peripheral circulation. However, the relationship between 
 
plasma amino acid levels and fat content, particularly in a specific body fat deposit, has 
not been evaluated in humans. 
Visceral obesity has been reported to represent a clinical intermediate 
phenotype reflecting the relative incapability of subcutaneous adipose tissue to act as a 
protective energy depot, leading to ectopic fat deposition in visceral adipose, skeletal 
muscle, liver, heart and other tissues18, 19. Thus, visceral obesity may be both a marker 
of a dysmetabolic state and a cause of metabolic syndrome20. Waist circumference and 	
bioelectrical impedance have been reported to be better markers of visceral fat 

accumulation than body mass index. However, these approaches are insufficient to 
diagnose visceral obesity21-23. Although both computed tomography (CT) and magnetic 
resonance imaging (MRI) achieve a reliable prediction of visceral fat24, 25, such high-
cost and low-throughput measurements are unsuitable for primary diagnosis. 
In this study, we first determined the plasma amino acid profile of human 
subjects who underwent CT scans for estimation of visceral fat area (VFA). Next, each 
plasma amino acid level was compared between low- and high-VFA groups to assess its 
discriminant power. Finally, a discriminant analysis with selected amino acids was 
examined with the multivariate logistic regression analysis “AminoIndex” and an 	
additional assessment was made with ROC curve analysis. 


 
Subjects and Methods 
Subjects 
A total of 1,449 subjects (985 males and 464 females) who had undergone 
comprehensive health screening tests between January 2008 and June 2009 at the Center 
for Multiphasic Health Testing and Services, Mitsui Memorial Hospital, and the 
Kameda Medical Center Makuhari were enrolled. Subjects were divided into two 
groups according to visceral fat area (VFA) volumes calculated from CT images: high- 	
VFA (100 cm2, n=867) and low-VFA (<100 cm2, n=582). These VFA areas were 

chosen because previous studies have reported that the mean number of metabolic risk 
factors in Japanese subjects with VFA100 cm2 is significantly higher than in those with 
VFA<100 cm2, irrespective of BMI26. Subjects were provided with no medical 
treatments before examination and blood sampling. The protocol was approved by the 
Ethical Committees of Mitsui Memorial Hospital and Kameda Medical Center 
Makuhari.  
In Japan, regular health check-ups for employees are legally mandated; thus, 
the majority of the subjects enrolled in the study did not have serious health problems. 
In addition, most or all of the costs of the health screenings are paid by the company for 	
which the individual works or by each individual. In addition, there are several options 

to choose from in the health screening program. The option chosen is up to each 
individual, not to the physicians or the company for which the individual works. 
Therefore, the study population was thought to not be enriched for any particular 
disease condition. 

Analyses of metabolic parameters 
Blood samples were taken from the subjects after an overnight fast. Serum levels of 
 	
total cholesterol (TC), HDL-cholesterol (HDL-C), and triglycerides (TG) were 
determined enzymatically. Plasma glucose was measured by the hexokinase method, 
and hemoglobin A1c (HbA1c) was determined using the latex agglutination 
immunoassay. Systolic and diastolic blood pressures were measured twice on the same 
day, and the mean value was used in the analysis. BMI was calculated as weight in 
kilograms divided by height in meters squared.  
 	
Measurement of abdominal fat area by CT scan 

Subcutaneous and visceral fat areas visualized on a CT scan at the level of the umbilicus 
were measured using Fat Scan software (N2 System Co., Osaka, Japan). All CT scans 
were performed in the supine posture using a CT scanner (SOMATOM Sensation 
Cardiac 64, Siemens, Germany). The VFA was defined as the intraperitoneal fat bound 
by the parietal peritoneum or transversalis fascia, excluding the vertebral column and 
paraspinal muscles. The SFA was defined as the fat superficial to the abdominal and 
back muscles. A region of interest drawn around the external margin of the dermis was 
used to calculate the total abdominal fat (TAF) area. The SFA was obtained by 
subtracting the VFA from the TAF. 	
 

Plasma amino acid profiling 
Blood samples (5 ml) were taken from forearm veins after an overnight fast in 
collection tubes containing EDTA-2Na (Terumo, Tokyo, Japan) and immediately cooled 
on ice. Plasma was obtained by centrifugation at 3000 rpm for 15 min at 4°C and stored 
at −80°C until analysis. Before analysis, a 50 L portion of the plasma sample was 
added to 50 L of the internal standard solution and 100 L of acetonitrile, and the 
solution was mixed with a vortex-mixer as described previously2, 3. After mixing, the 
 

precipitate was removed by centrifugation at 15,000 rpm for 10 min at 4°C and the 
supernatant was used for further analysis. 
Plasma amino acid analysis was carried out with HPLC-ESI-MS following 
derivatization. A MSQ Plus LC/MS system (Thermo Fischer Scientific, Waltham, MA, 
USA) equipped with an electrospray ionization source was used in the positive 
ionization mode for selected ion monitoring (SIM). Xcalibur (TM) version 1.4 SR1 
software was used for data collection and processing. The HPLC separation system 	
consisted of an L-2100 (pump), L-2200 (autosampler), and L-2300 (column oven) 

(Hitachi High-Technologies Corporation, Tokyo, Japan). A Wakosil-II 3C8-100HG 
column (100 mm × 2.1 mm, 3 m) (Wako Pure Chemical Industries, Osaka, Japan) was 
used for the separation. The mobile phase consisted of eluent A (25 mM ammonium 
formate in water) and eluent B (water:acetonitrile=40:60). In this study, twenty-four 
compounds were measured as described previously2, 3: alanine (Ala), alpha-
aminobutyric acid (ABA), arginine (Arg), asparagine (Asn), citrulline (Cit), glutamic 
acid (Glu), glutamine (Gln), glycine (Gly), histidine (His), isoleucine (Ile), leucine 
(Leu), lysine (Lys), methionine (Met), ornithine (Orn), phenylalanine (Phe), proline 
(Pro), serine (Ser), threonine (Thr), tryptophan (Trp), tyrosine (Tyr), and valine (Val).  	


Statistical analysis 
A Welch t-test was used to analyze differences in demographic variables, biochemical 
variables, and the plasma amino acid concentration between the high- and low-VFA 
groups. Significance was set at p<0.05. The discriminative power of the amino acids for 
the high- and low-VFA groups was evaluated by the area under curve of the receiver 
operating characteristics27. To evaluate the correlation among the variables, VFA, and 
 
subcutaneous fat area (SFA), the Pearson correlation coefficient was calculated.  
 
Multivariate logistic regression analysis for diagnosing VFA 
In this study, we used the multivariate logistic regression analysis “AminoIndex” for 
diagnosing high-VFA subjects. The search for an optimal “AminoIndex” was performed 
using a previously described algorithm 10, 11, 28, based on a multivariate logistic 
regression model with amino acid concentrations as variables. All possible 	
combinations of variables were investigated with cross-validation and an assessment of 

discriminatory power with the area under the ROC curve (AUC). In this study, the 
maximum number of variables for each regression formulation was restricted to six to 
limit the degrees of freedom and avoid overfitting. In addition, the variance inflation 
factor (VIF) was calculated to determine the degree of multicollinearity when its cutoff 
value was set at 10. Next, the best model was defined as the one with the minimum AIC 
(Akaike's information criterion)29. All of the statistical and multivariate analyses were 
performed with MATLAB and GraphPad Prism. 
 
	
Results 

Characteristics of study subjects  
Age and body weight profiles for the high-VFA (100 cm2; n=867) and low-VFA 
groups (<100 cm2; n=582) are summarized in Table 1. Body weight was significantly 
higher in the high-VFA group than in the low-VFA group. Although the mean age was 
significantly different between the two groups, it was a negligibly small difference of 
4.1 years. 
 
 
The metabolic variables in visceral fat accumulation 
General metabolic variables for the high- and low-VFA groups are summarized in Table 
2. Waist circumference, body mass index (BMI), triglyceride levels, plasma glucose 
level, systolic blood pressure, diastolic blood pressure, HbA1c and LDL cholesterol 
showed significant increases in the high-VFA group compared to the low-VFA group, 
with positive Pearson correlations with VFA value (n=1449). In contrast, only HDL 
cholesterol was significantly lower in the high-VFA group compared to the low-VFA 	
group. Next, the discriminative performance of each parameter was evaluated by ROC 

analysis (ROC_AUC in Table 2). As expected, there were close relationships between 
the Welch t-test and ROC_AUC because of the binominal distribution in the two 
groups30. Waist circumference and BMI gave higher Pearson correlations, greater than 
0.6 (n=1449), not only for visceral fat area (VFA) but also for subcutaneous fat area 
(SFA), without specificity between these different fat types (Table 2 and Figure 1). 
 
Plasma amino acid profile in visceral fat accumulation  
Plasma amino acid profiles are shown in Table 2. The Welch t-test indicated that the 
mean values of Glu, Val, Leu, Ile, Tyr, Ala, Phe, Pro, Lys, Orn, Trp, Met, His and ABA 	
were significantly higher in the high-VFA group, with a positive correlation with VFA. 

By contrast, Gly, Ser, Gln and Asn were significantly lower in the high-VFA group, 
with a negative correlation with VFA.  
The discriminative characteristics of each amino acid were also evaluated with 
ROC_AUC values (Table 2). Glu, Val, Leu, Ile, Tyr, Ala, Phe, Pro, Lys, Orn, Trp, Met, 
His and ABA were higher in the high-VFA group with statistical significance (p<0.001), 
whereas Gly, Ser, Gln and Asn were lower. Glu and Val gave higher Pearson 
correlations, more than 0.4, specifically for VFA, while lower correlation coefficients 
 
were found for SFA (Table 2 & Figure 1). Other BCAAs, Tyr and Ala, showed similar 
specificity and higher levels of correlation with VFA. 
 
Multivariate logistic regression analysis for discrimination between high-VFA and 
low-VFA groups 
According to the results described above, it was suggested that further improvement in 
discrimination capability could be achieved using a multivariate function using plasma 	
amino acid profiles. A multivariate logistic regression analysis, “AminoIndex”, was 

performed with selected variables. For discrimination between the high- and low-VFA 
groups, a formula incorporating six amino acids (Ala, Gly, Glu, Trp, Tyr, BCAA) was 
developed, and the formula [-3.5250]+[0.0379]Glu+[-
0.0070]Gly+[0.0034]Ala+[0.0196]Tyr+[-0.0216]Trp+[0.0054]BCAA was modeled, 
based on the procedure described in the Subjects and Methods. Figure 2 shows the ROC 
curve and the distribution plot of the obtained index, where it exhibits an area under 
ROC curve of 0.81 (95% confidence interval; 0.78 to 0.83), with higher sensitivity and 
specificity by 80% and 65%, respectively (a cutoff value 0.05). 
 	
 

Discussion 
Physical inactivity, diet, and inherited predisposition are the predominant causes of 
excessive fat accumulation in adipose tissue. Obesity has become a major health 
concern worldwide and is related to a number of cardiovascular and metabolic disorders 
including insulin resistance, hyperlipidemia, and non-alcoholic fatty liver disease 
(NAFLD)31-33. Recent studies have shown that visceral fat tissue, rather than 
subcutaneous fat tissue, secretes adipokines such as TNF-α and IL-6 and that the levels 
 
of these adipokines in the peripheral circulation are strongly correlated with the 
development of insulin resistance34 and the occurrence of cardiovascular disease35. 
Using CT imaging, visceral fat area (VFA) is generally defined as the sum of the 
intraperitoneal fat area, while subcutaneous fat area (SFA) is defined as the sum of the 
extraperitoneal fat area between the skin and muscle24. Previous studies have found that 
if the visceral fat level is high, the risk of myocardial infarction and cerebral infarction 
drastically increases, even if the subject does not have hypertension, diabetes or 	
hyperlipidemia20, 36. In addition, visceral fat has been reported to be associated with 

NAFLD, and an increase in its content is considered a potential therapeutic target in the 
treatment of NAFLD37. Thus, visceral fat accumulation is a potential risk factor and an 
early diagnostic marker for obesity-related diseases. Therefore, there is a critical need to 
elucidate the molecular pathogenesis of visceral obesity so that strategies can be 
developed for its prevention and treatment. 
In this study, we conducted plasma free amino acid profiling in 1449 human 
subjects who underwent comprehensive health check-ups and CT scans for VFA and 
SFA measurements. We found that the majority of plasma amino acids were specifically 
altered with increased VFA, but not with SFA. Abdominal CT scans and waist 	
circumferences are most frequently used for VFA prediction in clinical settings22, 24. 

However, CT scanners frequently have mechanical problems that require money, time 
and labor to repair, and these dysfunctions can even present radiation threats. Waist 
circumference is a noninvasive method to measure VFA, but it is subject to variation 
depending on the person who takes the measurement and the measurement site used. 
Additionally, the waist circumference combines subcutaneous fat and visceral fat 
leading to an underestimation of VFA38. In fact, waist circumference in this study gave 
 
relatively higher Pearson correlations for both SFA and VFA, but did not have any 
specificity for either fat type. Bioelectrical impedance has been reported as a simple 
predictor of VFA, but a recent study showed that it provides an approximation of the 
total abdominal adipose fat measured by MRI, not VFA21. Thus, the amino acid profile 
and regression index presented here could be an approach for making primary 
measurements for specific VFA prediction.  
Our results showed significant differences in plasma amino acids in accordance 	
with the degree of VFA. We found that there were significantly higher levels of Glu, 

BCAAs, Tyr, Ala, Phe, Pro, Lys, Orn, Trp, Met, His and ABA in the high-VFA group, 
while there were lower levels of Gly, Ser, Gln and Asn. The underlying mechanism by 
which these amino acids change in response to VFA level is unclear; however, 
metabolic alternations, such as lowered insulin sensitivity, may contribute to altered 
amino acid levels. In the present study, BCAAs were significantly correlated with VFA, 
but not SFA. Elevation of plasma BCAAs has been reported in both humans and animal 
models of obesity14-16. Rosenthal et al. estimated that adipose tissue is second only to 
skeletal muscle in its capacity to catabolize BCAAs and that the capacities of skeletal 
muscle and adipose tissue are 6–7-fold larger than that of liver39. A previous study in 	
mice showed that tissue-specific alterations in BCAA metabolism in liver and adipose 

tissue, but not in skeletal muscle, can contribute to an elevation in plasma BCAA levels 
in obese individuals15. Furthermore, a recent study demonstrated the importance of 
adipose BCAA enzymes and the BCAA catabolizing capacity of adipose tissue in 
determining circulating BCAA levels in obese mice and in possibly influencing the 
development of associated insulin resistance40. Thus, our data support previously 
reported findings and provide strong evidence for the importance of plasma BCAAs as a 
 
potential marker for visceral fat specific metabolic changes. It has been suggested that 
BCAAs may be responsible for some of the beneficial effects of high-protein diets, 
including improved body weight control41, 42, and may decrease adiposity and hepatic 
steatosis12. Similarly, BCAAs improve muscle glucose uptake, whole body glucose 
metabolism, and oxidation43. Therefore, the plasma amino acid profiling technique 
presented here could be a potential tool for nutritional treatments for obesity and 
metabolic syndrome. 	
Our data showed significant changes in glucogenic amino acids, such as Gly, 

Ala and Gly; Gly and Ser are two amino acids that had negative correlations with VFA. 
The reason for the reduction of Gly in the plasma of the high-VFA group is unclear. 
However, it has been reported that in hepatocytes glucose production from both Gly and 
Ser is increased in diabetic individuals, while this type of glucose production is a low 
under healthy conditions44. Gly and Ser are synthesized from glycolytic intermediates 
via 3-phosphoglycerate dehydrogenase, which is an NAD-linked enzyme that converts 
3-phosphoglycerate (3-PG) to 3-phosphohydroxypyruvate and is the rate-limiting step 
of de novo serine biosynthesis45. Glyceroneogenesis can also produce 3-PG, so it is 
possible that serine can be synthesized in the liver by phosphoenolpyruvate 	
carboxykinase (PEPCK). Thus, changes in glyceroneogenesis in adipose tissue and liver 

due to increased demand for glycerol and glyceride for triglyceride synthesis may affect 
serine biosynthesis and the subsequent Ser and Gly levels in the peripheral circulation46. 
We tested another AminoIndex with Gly in addition to BCAAs asexplanatory variables, 
and we confirmed that it has enough discrimination power to distinguish between the 
high- and low-VFA groups (data not shown). Although the levels of several other amino 
acids, including Tyr and Phe, change depending on VFA levels, the reasons are unclear. 
 
Therefore, further studies elucidating the mechanisms behind alternations in plasma 
amino acid levels are needed.  
In conclusion, the results suggest that measurement of the levels of different 
amino acids in plasma samples is a useful approach for understanding the metabolic 
implications of obesity and can be used as a predictor of elevated visceral obesity in 
humans.  
 	
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Figure legends 
 
Figure 1. Scatter plots of waist circumference (cm), BMI (kg/m2), Glu (mol/l), Val
(mol/l), Leu(mol/l), Ile(mol/l), Tyr(mol/l), Ala(mol/l) and Trp(mol/l) versus 
VFA (cm2) and SFA (cm2); these plots have positive Pearson correlation coefficients, 
whereas the plots of Gly (mol/l) versus VFA (cm2) and SFA (cm2) have negative 
Pearson correlation coefficients. Representative images (bottom) of visceral fat obesity 	
(left) and subcutaneous fat obesity (right) are shown where the distribution of 

abdominal fat was measured by FatScan software based on CT scans at the level of the 
umbilicus. The visceral fat area is represented in red, and the subcutaneous fat area is 
pink. 
 
Figure 2. Performance of the multivariate regression model “AminoIndex” for 
discrimination between high-VFA and low-VFA groups. (A) ROC curves for the high-
VFA group versus the low-VFA group (dotted). (B) Distribution plots of AminoIndex 
values for high-VFA and low-VFA groups. 
 	
 
Table 1. Characteristics of study subjects 
Significant differences between the high-VFA (100 cm2) group and the low-VFA group 
(<100 cm2) were evaluated by the Welch t-test: *** represents p<0.001. 
 
 
 
VFA<100 cm2 
means±SD 
VFA100 cm2 
means±SD 
p 
value
n (male, female) 582 (304, 278) 867 (681, 186) 
Age (years) 55.7±12.6 59.8±10.9 *** 
Body weight (kg) 58.0±10.1 69.5±11.0 *** 

 
Table 2. The discriminative capacity for the high-VFA group (100 cm2) vs. the 
low-VFA group (<100 cm2) and the Pearson correlation coefficients with VFA and 
SFA as variables. 
Numbers are means ± SD. The significance of the differences between the high-VFA 
group (100 cm2) and the low-VFA group (<100 cm2) were evaluated by the Welch t-
test: * p<0.05, ** p<0.01, and *** p<0.001. The areas under the curve of receiver-
operating characteristic curves (ROC_AUC) were evaluated with 95% CI and P-values: 	
* p<0.05, ** p<0.01, and *** p<0.001. Variables were ordered by ROC_AUC. For 

evaluation of the correlations among metabolic variables, visceral fat area (VFA), and 
subcutaneous fat area (SFA), the Pearson correlation coefficient was used. 
 

 VFA<100 cm2 
means±SD 
n=582
VFA100 cm2 
means±SD 
n=867
ROC_AUC  (95% CI) Coefficient of 
correlation 
VFA    SFA 
Metabolic variables 
Waist circumference (cm) 79.1±7.6 89.6±7.5 *** 0.84  (0.82  -  0.86) *** 0.66 0.71 
Body mass index (kg/m2) 21.7±2.6 25.2±3.0 *** 0.82  (0.80  -  0.84) *** 0.61 0.72 
Triglycerides (mg/dl) 94.1±52.8 146.4±117.0 *** 0.71  (0.68  -  0.74) *** 0.30 0.08 
Plasma glucose (mg/dl) 94.0±14.0 104.8±22.3 *** 0.69  (0.66  -  0.71) *** 0.31 0.09 
HDL cholesterol (mg/dl) 65.1±16.2 55.2±13.4 *** 0.68  (0.66  -  0.71) *** -0.33 -0.15 
Systolic blood pressure (mmHg) 118.6±18.4 130.0±17.7 *** 0.68  (0.66  -  0.71) *** 0.33 0.17 
Diastolic blood pressure (mmHg) 74.3±11.1 81.4±10.7 *** 0.68  (0.65  -  0.71) *** 0.33 0.14 
HbA1c (%) 5.3±0.6 5.6±0.7 *** 0.64  (0.61  -  0.67) *** 0.24 0.07 
LDL cholesterol (mg/dl) 122±27.7 127.2±31.2 ** 0.55  (0.52  -  0.58) ** 0.07 0.14 
Plasma amino acids (mol/l) 
Glutamate 37.3±16.1 54.6±21.3 *** 0.75  (0.73  -  0.78) *** 0.49 0.21 
Valine 224.5±38.0 256.5±43.7 *** 0.71  (0.68  -  0.74) *** 0.42 0.08 
Leucine 114.1±22.2 132.0±25.3 *** 0.70  (0.68  -  0.73) *** 0.39 0.04 
Isoleucine 66.1±14.8 77.5±17.7 *** 0.69  (0.66  -  0.72) *** 0.39 0.06 
Tyrosine 73.6±14.8 83.8±16.3 *** 0.68  (0.65  -  0.71) *** 0.40 0.18 
Alanine 364.8±79.2 415.2±87.3 *** 0.67  (0.64  -  0.70) *** 0.33 0.15 
Glycine 258.4±63.2 227.6±48.0 *** 0.66  (0.63  -  0.69) *** -0.31 -0.12 
Phenylalanine 62.0±10.8 66.5±10.9 *** 0.63  (0.61  -  0.66) *** 0.27 0.07 
Proline 142.3±40.4 159.4±40.5 *** 0.63  (0.60  -  0.66) *** 0.24 0.05 
 
Lysine 198.2±33.2 211.5±30.9 *** 0.62  (0.59  -  0.65) *** 0.23 0.02 
Ornithine 54.0±13.4 59.3±13.9 *** 0.61  (0.59  -  0.64) *** 0.20 0.02 
Tryptophan 58.0±10.0 61.3±10.3 *** 0.60  (0.57  -  0.63) *** 0.20 0.02 
Serine 115.1±18.3 109.4±17.7 *** 0.59  (0.56  -  0.62) *** -0.17 -0.04 
Methionine 27.1±6.1 28.4±4.9 *** 0.58  (0.55  -  0.61) *** 0.16 -0.01 
Histidine 79.9±10.5 82.6±11.1 *** 0.57  (0.54  -  0.60) *** 0.14 0.06 
α-Aminobutyric acid 22.0±6.5 23.7±6.9 *** 0.57  (0.54  -  0.60) *** 0.11 0.06 
Glutamine 591.7±79.8 579.2±75.7 ** 0.55  (0.52  -  0.58) ** -0.09 -0.05 
Asparagine 45.2±7.1 44.4±6.8 * 0.53  (0.50  -  0.56) * -0.08 -0.15 
Threonine 115.8±25.0 117.6±25.2  0.52  (0.49  -  0.55)  0.05 0.00 
Arginine 96.9±19.0 97.6±17.1  0.51  (0.48  -  0.54)  0.01 -0.08 
Citrulline 33.5±8.2 33.9±8.5  0.51  (0.48  -  0.54)   0.01 -0.12 



